Information Provided By:
Fly News Breaks for November 7, 2018
DXCM
Nov 7, 2018 | 05:16 EDT
Piper Jaffray analyst JP McKim raised his price target for DexCom to $157 saying the company reported Q3 results that beat elevated expectations. The most important takeaway from the earnings call is that "new patient additions are up significantly and that the pipeline has more than doubled what is was the prior year," McKim tells investors in a research note. He sees lots to like in the quarter and believes G6 is "truly a game changing platform." The analyst reiterates an Overweight rating on DexCom.